News Release: Research
Feb. 28, 2011
Technology Transfer Office at Emory University Hosts 5th Annual Celebration of Technology and Innovation
WHAT: Fifth Annual Celebration of Technology and Innovation, Program and Reception
WHEN: Thursday, March 10, 4:30 p.m.
WHERE: Emory Conference Center, Silver Bell Pavilion, 1615 Clifton Rd., Atlanta, GA 30322
KEYNOTE SPEAKER: Dan Myers, CEO, Alimera Sciences
Dan Myers is co-founder of Alimera Sciences, Inc., and has served as its president and CEO since 2003. Alimera is an emerging pharmaceutical company focused on diseases of the eye, with particular emphasis on drug delivery systems for retinal disease. Alimera’s lead product, Iluvien, is an ocular implant for the treatment of diabetic macular edema, and is awaiting FDA approval.
Under his leadership, Alimera has raised venture funding totaling approximately $106 million. Myers also led the company through a successful initial public offering in April 2010, raising $72 million in additional capital. Alimera was awarded the Georgia Bio “Deal of the Year” in 2004 and 2005 as well as the Southeastern Bio “Strategic Deal of the Year” in 2010.
Myers was previously a founding member of Novartis Ophthalmics and served as vice president of sales and marketing and later as president from 1997-2002. He has 28 years of sales, marketing and general management experience in the ophthalmic pharmaceutical industry through tenures at Novartis, Allergan and Johnson & Johnson.
EMORY ANNUAL CELEBRATION WINNERS 2011:
Start-up of the Year: Apica Cardiovascular
Vinod Thourani, MD (Surgery) and Ajit Yoganathan (Biomedical Engineering)
Deal of the Year: Anti-flu Antibodies
Rafi Ahmed, PhD, and Jens Wrammert, PhD (Microbiology & Immunology)
Innovation of the Year: Periuretheral Injection Technology for Treating Incontinence
Niall Galloway, MD, and James Galloway, MD (Urology)
Significant Event: Ipsen Biopharm Limited
John (Pete) Lollar, III, MD (Pediatrics)
Over the past two decades, through its Office of Technology Transfer, Emory University has launched 51 start-up companies and received more than $788 million in licensing revenues from drugs, diagnostics, devices and consumer products. Currently, more than 50 products are in various stages of development or regulatory approval, with 27 having reached the marketplace and 12 more in human clinical trials.
For more information @ http://www.ott.emory.edu